Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a development stage enterprise, covers the month of November 2023. The company is headquartered in Melbourne, Australia, and files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance updates rather than financial performance data.
Material Changes
The primary material event disclosed is the cessation of securities trading for the ticker symbol "ATH," as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document serves primarily to incorporate the notification of the cessation of securities into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status of the "ATH" ticker symbol and the implications of its cessation.
- Confirm the impact of the cessation on existing Registration Statements (Files No. 333-251073, 333-248980, 333-228671, 333-274816, 333-251647, 333-231417, and 333-250076).
- Review the full text of Exhibit 99.1 for details regarding the cessation notification.